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ABSTRACT 
 
 
Background: Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder 
cancer has been shown to improve all cause and cancer specific mortality. We evaluate 
whether a diagnosis of carcinoma in situ (CIS) at the time of initial transurethral resection of 
bladder tumor (TURBT) has an oncological impact on the response of NAC in patients 
undergoing a radical cystectomy.  
 
Objective: We aim to compare the pathological response and overall survival between patients 
with and without CIS receiving NAC followed by radical cystectomy (RC). 
 
Design, Setting and Participants: From 2000 – 2013, data on patients with cT2-T4aN0-3M0 
urothelial carcinoma of the bladder who received at least 3 cycles of NAC  or induction 
chemotherapy followed by RC were retrospectively collected from 19 centers across Europe 
and North America. 
 
Intervention: Neoadjuvant or induction chemotherapy followed by RC. 
 
Outcome Measurements and Statistical Analysis: Our primary outcome was pathological 
response with secondary outcome being overall survival. Multivariable analysis was performed 
to determine the independent predictive value of CIS on pathological response.  
 
Results: 1213 patients were included for analysis with 21.8% having concomitant CIS. 
Baseline clinical and pathologic characteristics of the ‘CIS’ versus ‘no CIS’ groups were similar. 
There was no difference in the pathological response between the two arms when response 
was defined as pT0N0 (17.9% with CIS vs 21.9% without CIS) or ≤pT1N0 (42.8% with CIS vs 
37.8% without CIS). On Cox Regression model for overall survival for the cN0 cohort using 
clinicopathological data, the presence of CIS was not associated with survival (HR 0.86 (95% 
CI 0.63-1.18; p=0.35). The presence of LVI (HR 1.41, 95% CI 1.01-1.96; p=0.04), 
hydronephrosis (HR 1.63, 95% CI 1.23-2.16; p=0.001) and use of ddMVAC regimen (HR 0.57, 
95% CI 0.34-0.94; p=0.03) were associated with survival. For the whole cohort, presence of 
CIS was not associated with any alteration in survival (HR 1.05 (95% CI 0.82-1.35; p=0.70)). 
 
 
Conclusion: In this multicenter, real-world cohort, CIS status did not affect pathologic 
response to neoadjuvant or induction chemotherapy. This study is limited by its retrospective 
nature and lack of concordance with respect to chemotherapy regimens.   
 
 
INTRODUCTION 
 
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and 
bilateral pelvic lymph node dissection is considered the standard of care for patients with 
muscle invasive bladder cancer (MIBC) who are eligible to receive this multimodal therapy. This 
approach has been shown to improve all-cause and cancer-specific mortality compared to RC 
alone [1,2]. The pathologic response, defined as either no residual carcinoma (pT0N0) or no 
residual MIBC (≤pT1N0), is considered a surrogate endpoint for overall survival [3]. Patients 
with residual MIBC have a high risk of recurrence and subsequent death from bladder cancer 
[2].  
 
In current clinical practice, the effect on CIS on chemotherapy response and outcomes remains 
unclear. . with limited and retrospective  evidence in current literature. We hypothesize that 
there is no oncological difference in outcome in patients diagnosed with CIS on initial TURBT 
who subsequently receive NAC prior to RC. We tested this hypothesis in a large international 
consortium. We compared the pathologic response to NAC and overall survival in patients with 
and without concomitant CIS at TURBT undergoing RC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENTS & METHODOLOGY 
 
 
Study population 
 
From 2000 – 2013, patients were retrospectively identified with MIBC (cT2-T4aN0-3M0) who 
were managed with pre-operative systemic chemotherapy followed by RC at 19 centers across 
Europe, Canada and the USA. These centers collectively agreed to data share and this was 
approved by their governing Institutional Review Boards. The term neoadjuvant chemotherapy 
(NAC) is conventionally used only for patients with cN0M0 bladder cancer. Here, we also 
included patients receiving induction chemotherapy for cN1-3M0 disease under the term NAC. 
 
The study population was divided into patients with and without CIS at TURBT. All patients had 
urothelial carcinoma of the bladder. Mixed histology with squamous and/or glandular 
differentiation was allowed, but no other variant histology. All patients received at least three 
cycles of NAC prior to RC.  
 
Information regarding demographics, clinical staging, chemotherapy regimen, and other 
treatment parameters was obtained. Additionally, the pathological outcome after cystectomy 
was retrieved. All centers used the American Joint Committee on Cancer (AJCC) criteria for 
pathologic assessment. There was no central review. 
 
Statistical Analysis 
 
Clinical and pathologic data were compared between groups.  For variables with non-normal 
distribution, data were presented as median and interquartile range (IQR), and the respective 
groups were compared using the Mann-Whitney U test. Categorical variables were compared 
using the χ2 test. Multivariable logistic regression analysis of selected variables (age, cT stage, 
gender, and type of chemotherapy regimen) was used to define factors predicting pCR and 
pPR. For comparison of adjusted pathologic response rates, the odds ratio (OR) was reported, 
and the 95% confidence interval (CI) was calculated with bootstrapping. The multivariable Cox 
proportional hazards regression model for survival was used to assess hazard ratios (HRs) for 
variables of interest (gender, type of chemotherapy regimen, surgical margin, extent of lymph 
node dissection, and presence of pPR). Significance was set at p value <0.05. Analyses were 
performed using SPSS v.21 software (IBM SPSS Statistics; IBM Corp, Armonk, NY, USA). The 
primary outcome was pathologic response defined as either pT0N0 or ≤pT1N0 in RC 
specimens. Multivariate analysis was performed to identify factors predictive of either outcome. 
Two multivariable binary regression models were created, one including all cN stages and one 
only for patients with cN0.  A multivariable Cox regression model for overall survival was also 
generated. Significance was set at p value < 0.05. 
RESULTS 
 
After applying our selection criteria from the total of 1865 patients, 1253 met our criteria. The 
CIS status was not present in 40 patients and they were excluded from the analysis. Overall 
1213 patients were chosen, including 823 patients who were cN0, 117 cNx and 273 who were 
cN1-3. Concomitant CIS was reported in 21.8% of patients. Table 1 shows the clinical and 
pathological features in both the “CIS” and “no-CIS” cohorts. Seventeen percent of patients 
who had no CIS on initial TURBT initially were subsequently diagnosed to have CIS on final 
pathology at the time of RC on final pathology.  
 
 The no-CIS patients had a higher baseline risk with respect to cT stage, cN stage, and 
hydronephrosis, whereas the rate of lymphovascular invasion (LVI) was higher in the CIS 
patients. The time from NAC to cystectomy was significantly longer in patients with CIS (17 
weeks) versus those without CIS (16 weeks; p = 0.006).  
 CIS No CIS P value 
 n(%) n(%)  
Number of patients 
 
265 (21.8) 948 (72.2)  
Median age (years) 
 
64 64 0.75 
Male gender 
 
199 (75.1) 722 (76.1) 0.91 
smokers 
 
200 (71.9) 702 (69.7) 0.89 
Hydronephrosis at presentation 
 
63 (23.8) 305 (32.2) 0.03* 
Clinical stage at initial TURBT    
     T2 161 (60.8) 499 (52.6) 0.06 
     T3 72(27.2) 309 (32.6)  
     T4 32 (12.1) 140 (14.8)  
    
      Node negative 188 (70.9) 635 (67.0) 0.05 
      Node positive 46 (17.4) 277 (23.9)  
     Nodal status unknown 31 (11.7) 86 (9.1)  
    
TURBT pathology    
     Urothelial carcinoma (UC) 236(89.1) 839(88.5) 0.94 
     UC with squamous differentiation 22 (8.3) 85 (9.0)  
     UC with glandular differentiation 7 (2.6) 24 (2.5)  
     Lymphovascular invasion 59 (22.3) 163 (17.2) 0.04* 
 
Table 1: Baseline demographic and clinicopathological findings at initial TURBT 
 
The NAC regimens employed were gemcitabine-cisplatin (GC) in 608 (50.1%), methotrexate-
vinblastine-adriamycin-cisplatin (MVAC) in 401 (33.1%) and ‘other’ in 196 (16.2%). The NAC 
regimen was not recorded for the remaining patients (0.6%). The median follow up was 1.6 
years (ranged 0.5 – 3.5years). 
 
 
The pathological response for all patients regardless of cN status showed no significant 
difference according to CIS status (Table 2). However, when only cN0 patients were 
considered, the down-staging to ≤pT1N0 occurred more frequently in the CIS group (53.0%) 
than in the non-CIS group (41.7%; p=0.007). CIS was found more frequently in the RC 
specimen in patients who had CIS prior to treatment (p = <0.001). Down-staging to pT0N0 did 
not differ according to CIS status. 
 
 
 CIS No CIS P value 
 n(%) n(%)  
Number of patients 265 (21.8) 948 (72.2)  
 
    
Chemotherapy (NAC) regimen    
     ddMVAC 50 (18.9) 211 (22.3) 0.18 
     GC 133 (50.2) 475 (50.1)  
     Other 49 (18.5) 147 (15.5)  
    
Number of chemotherapy cycles   0.07 
     3 122 (46.0) 371 (39.1)  
     4 111 (41.9) 494 (52.2)  
     >4 32 (12.1) 83 (8.8)  
    
Median time between TURBT and NAC 
(weeks) 
6 5 0.13 
Duration of NAC (weeks) 9 9 0.35 
Median time between NAC and RC (weeks)    17 16 0.006* 
     31 (11.7) 86 (9.1)  
    
Final pathology at RC    
     No residual disease (pT0N0) 46(17.9) 204 (21.9) 0.16 
     Non muscle invasive disease(≤pT1N0) 110 (42.8) 352 (37.8) 0.15 
     CIS only 43(16.2) 99(10.4) 0.01 
     Associated CIS  116 (43.8) 248 (26.2) 0.001* 
 
Table 2: Chemotherapy regimens and final pathological results 
 
 
Table 3 summarizes the multivariable analysis assessing potential risk factors for pathologic 
down-staging in all patients (cN0-3). cN1-3 status (compared to cN0; OR 0.48, 95% CI 0.32-
0.72; p<0.001) was an independent predictor of lower pT0N0 and ≤pT1N0 rates (compared to 
cN0; 0.44, 95% CI 0.31-0.61; p<0.001). The presence of CIS (OR 0.66 (95% CI 0.45-0.98; 
p=0.04) was an independent predictor of lower pT0N0 rate. Table 4 summarizes the 
multivariate analysis assessing potential risk factors for pathologic down-staging for patients 
with N0 disease. 
 
 
 
 
  
Variables ≤ypT1N0  ypT0N0  
 OR (95%CI) p OR (95%CI) p 
Gender* 
Female 
Male 
 
1 
0.75(0.66,1.04) 
 
 
0.08 
 
1 
0.77(0.38,1.55) 
 
 
0.46 
cT stage 
cT2 
              cT3-4 
 
1 
0.83(0.64,1.08) 
 
 
0.17 
 
1 
0.85(0.63,1.16) 
 
 
0.31 
NAC regimen 
MVAC 
              ddMVAC 
              GC 
Other 
 
1 
1.49(0.93,2.38) 
1.39(0.90,2.15) 
1.19(0.72,1.97) 
 
 
0.09 
0.13 
0.49 
 
1 
1.70(0.95,3.03) 
1.46(0.84,2.51) 
1.54(0.83,2.84) 
 
 
0.07 
0.17 
0.17 
cN stage 
N0 
N+ 
Nx 
 
1 
0.44(0.31,0.61) 
0.74(0.47,1.16) 
 
 
<0.001 
0.19 
 
1 
0.48(0.32,0.72) 
0.66(0.37,1.15) 
 
 
<0.001 
0.14 
CIS 
No 
Yes 
 
1 
0.93 (0.67, 1.27) 
 
 
0.64 
 
1 
0.66 (0.45, 0.98) 
 
 
0.04 
Table 3. Predictors of pT0N0 and ≤ypT1N0 for the entire cohort 
 
 
Variables ≤ypT1N0  ypT0N0  
 OR (95%CI) p OR (95%CI) p 
Gender* 
Female 
Male 
 
1 
0.73(0.49,1.09) 
 
 
0.13 
 
1 
0.88(0.56,1.38) 
 
 
0.58 
cT stage 
cT2 
              cT3-4 
 
1 
0.66(0.48,0.91) 
 
 
0.01 
 
1 
0.71(0.49,1.03) 
 
 
0.07 
NAC regimen 
MVAC 
              ddMVAC 
              GC 
Other 
 
1 
1.32(0.72,2.44) 
1.17(0.66,2.08) 
0.88(0.45,1.74) 
 
 
0.36 
0.56 
0.72 
 
1 
1.23(0.62,2.46) 
1.03(0.53,1.98) 
0.97(0.45,2.11) 
 
 
0.54 
0.93 
0.94 
CIS 
No 
Yes 
 
1 
1.18 (0.81, 1.72) 
 
 
0.38 
 
1 
0.79 (0.51, 1.23) 
 
 
0.30 
Table 4. Predictors of pT0N0 and ≤ypT1N0 for cN0 
 
On Cox Regression model for overall survival for the cN0 cohort using clinicopathological data 
(Table 5), the presence of CIS was not associated with survival (HR 0.87 (95% CI 0.64-1.89; 
p=0.38)). The presence of LVI (HR 1.44, 95% CI 1.04-2.00; p=0.03), hydronephrosis (HR 1.58, 
95% CI 1.18-2.11; p=0.002) and use of ddMVAC regimen (HR 0.58, 95% CI 0.35-0.96; p=0.03) 
were associated with survival outcomes. 
 
 
 
  
Variables OS  
 HR (95%CI) p 
 
Age 
 
1.00(0.99,1.01) 
 
0.40 
cT stage 
cT2 
              cT3-4 
 
1 
0.14(0.88,1.48) 
 
 
0.31 
NAC regimen 
MVAC 
              ddMVAC 
              GC 
Other 
 
1 
0.58(0.35,0.96) 
1.00(0.65,1.55) 
1.11(0.68,1.80) 
 
 
0.03 
0.98 
0.68 
LVI 
No 
Yes 
Unknown 
 
1 
1.44(1.04,2.00) 
1.13(0.83,1.54) 
 
 
0.03 
0.44 
Hydronephrosis 
No 
Yes 
              Unknown 
 
1 
1.58(1.18,2.11) 
1.33(0.93,1.92) 
 
 
0.002 
0.11 
CIS 
No 
Yes 
 
1 
0.87 (0.64, 1.89) 
 
 
0.38 
Table 5. Cox regression model for OS for cN0 cohort using pre-cystectomy data 
 
Assessing survival for the entire cohort (Table 6), cN+ status, presence of hydronephrosis and 
the use of ddMVAC were the predictors of overall survival. Presence of CIS was not associated 
with any alternation in survival (HR 1.06 (95% CI 0.83-1.36; p=0.65). 
 
Variables OS  
 HR (95%CI) p 
 
Age 
 
1.00(0.99,1.01) 
 
0.23 
cT stage 
cT2 
              cT3-4 
 
1 
1.23(0.99,1.51) 
 
 
0.06 
cN stage  
N0 
N+ 
              Nx 
 
1 
1.54(1.23,1.92) 
0.91(0.54,1.54) 
 
 
<0.001 
0.73 
NAC regimen 
MVAC 
              ddMVAC 
              GC 
Other 
 
1 
0.66(0.46,0.94) 
0.93(0.67,1.29) 
0.99(0.68,1.43) 
 
 
0.02 
0.66 
0.95 
LVI 
No 
Yes 
Unknown 
 
1 
1.25(0.96,1.65) 
1.13(0.89,1.45) 
 
 
0.10 
0.30 
Hydronephrosis 
No 
Yes 
 
1 
1.35(1.07,1.71) 
 
 
0.01 
              Unknown 1.32(0.98,1.77) 0.06 
CIS 
No 
Yes 
 
1 
1.06(0.83, 1.36) 
 
 
0.65 
Table 6. Cox regression model for OS for the entire cohort using pre-cystectomy data 
 
DISCUSSION 
For the management of muscle invasive bladder cancer is important to be able to better 
prognosticate based on the initial parameters on TURBT in view of a variable response to 
different neoadjuvant chemotherapy regimens. It is important to identify patients with muscle 
invasive bladder cancer who are less likely to respond and/or more likely to progress during 
NAC, and thus have less benefit[1-3]. Current literature indicates progress in research to 
identify those tumors with specific characteristics on initial TURBT to help prognosticate 
response rates with NAC [4]. Potential  factors associated with lower response to NAC may 
include tumor location at the bladder neck, and presence of hydronephrosis, sarcomatoid, small 
cell or micropapillary variant, while genomic alterations in DNA repair genes, e.g. ERCC2, Rb1, 
FANCC, ATM, also in HER2 gene, as well as the basal molecular subtype based on gene 
expression predict better response to cisplatin-based NAC. Ongoing clinical trials are 
evaluating the clinical utility of such molecular biomarkers. [4,5].  
 
CIS alone is regarded as high-risk non-MIBC because it is estimated that >50% of cases will 
progress to MIBC over time if left untreated. CIS in addition to papillary NMIBC  increases the 
risk of progression. When patients with CIS proceed to cystectomy, upstaging can occur in up 
to 55% of specimens compared to 6% of cases without CIS [4]. In patients diagnosed with CIS 
on initial TURBT there is a variable amount of published literature as to whether or not CIS itself 
may predicit  lower response rates to NAC [6].  
 
There are also published reports highlighting that CIS is associated with poorer prognostic 
implications, however there has been prospective Randomized controlled Trial to address the 
negative prognostic implications of CIS on pre-NAC TURBT [7]. Based on published data CIS 
may have potential prognostic impact and thus may be potentialprognostic biomarker for 
response in patients undergoing RC following NAC. However, isolated CIS at cystectomy is 
frequently observed and further studies aiming at understanding the biology and clinical effect 
of CIS in MIBC are warranted [7]. 
 
Whilst previous studies indicated a poorer prognosis on response rates with CIS diagnosed at 
initial TURBT in patients receiving NAC followed by cystectomy [8,9] a recent publication by 
Thomas et al. [7] and previous by Parker et al. [8] have indicated significantly decreased pCR 
rates at cystectomy among patients with pre-NAC CIS in their TURBT samples. This finding is 
noteworthy, because pCR is a frequently used early endpoint in clinical trial designs in the NAC 
setting for MIBC.  
 
Carcinoma in situ (CIS) is generally considered to be the precursor lesion for nonpapillary 
MIBCs [9], but comprehensive genomic data for CIS are not yet available, so this assumption 
awaits further experimental validation. Patients with either high-grade papillary nonmuscle-
invasive disease or CIS are currently treated with the same adjuvant therapy (intravesical 
Bacillus Calmette–Guerin [BCG] immunotherapy) after TURBT, but it is by no means clear that 
BCG produces comparable benefit in CIS and high-grade papillary tumors [10,11]. Many high-
grade papillary tumors ultimately become BCG unresponsive, so clinicians are then faced with 
the dilemma of whether to continue using a bladder-sparing regimen or to employ definitive 
surgery. The latter is certainly too aggressive for those patients whose tumors could be 
controlled by local therapy, but again there are no reliable tools to distinguish the tumors that 
have the potential to metastasize from those that do not. Muscle-invasive disease is managed 
with definitive local therapy (chemoradiation) or surgery (cystectomy) with or without 
perioperative systemic cisplatin-based chemotherapy to treat subclinical metastatic disease, 
but it is still not possible to further distinguish the patients who warrant chemotherapy from 
those who will not benefit from it. It would also be tremendously useful to have biomarkers that 
would enable patients and their physicians to choose between bladder-sparing regimens, such 
as chemoradiation [9]. 
 
A specific concern with respect to CIS in the bladder could relate to disease recurrence in the 
urethra or upper tracts after RC in the long term [12.13]. Takayanagi A et al. [12] have 
identified CIS and cancer invading the urethra on final pathology at RC to be risk factors 
for upper urinary tract recurrence. Volkmer et al. [13] identified the one of the risk factors for 
upper tract recurrence following  RC to be CIS (RR 2.3), history of recurrent bladder cancer 
(RR 2.6), cystectomy for non-muscle invasive bladder cancer (RR 3.8) and tumor involvement 
of the distal ureter in the cystectomy specimen (RR 2.7). Patients who underwent cystectomy 
for urothelial carcinoma and with at least 1 risk factor for upper urinary tract recurrence should 
have closer follow-up than those with non-urothelial histology or without any of these risk 
factors [13]. The overall rate of upper urinary tract recurrence at 5, 10 and 15 years were 
2.4%, 3.9% and 4.9%, respectively [13]. It is also important to note that CIS of the bladder 
has an inherent sampling error and tumor heterogeneity, which can make the identification of 
TURBT CIS difficult, in addition to the less judicious reporting of CIS in the past [7,13]. Once 
we have longer follow up in our series we plan to present data on urethra and upper tract 
recurrence in due course. 
 
It has  been shown that pT0 rates post RC are influenced by NAC regimens and prior TURBTs 
being performed [14]. Kukereja et al. [14] evaluated  pT0 status following NAC on final 
pathology can be attributed to the absence of residual disease (cT0) on transurethral resection 
of bladder tumor (TURBT) or to the effects of NAC. The authors found [14] that a complete 
TURBT may not predict pT0 at RC. A notable fraction of patients with cT0 bladders have locally 
advanced and/or lymph node-positive disease. These findings may be of value when 
counseling patients on bladder preservation strategies for muscle-invasive BC. 
 
. 
In our study, we  evaluated the pathologic and clinical outcomes in patients diagnosed with or 
without CIS on the initial TURBT prior to NAC followed by a RC. We  found no difference in the 
pathologic response between the two groups when response was defined either as pT0N0  or 
≤pT1N0. On Cox Regression model for overall survival for the cN0 cohort using 
clinicopathological data, the presence of CIS was not associated with survival (HR 0.87 (95% 
CI 0.64-1.89; p=0.38).  The presence of LVI at TURBT (hydronephrosis and less use of 
ddMVAC regimen were associated with shorter overall survival. For the whole cohort, presence 
of CIS was not associated with survival. We  found that CIS status at initial TURBT did not 
affect pathologic response to NAC. We also  acknowledge that the study is limited by its 
retrospective nature, and variability of NAC regimens, schedules and number of cycles given, 
as well as surveillance follow up logistics. As a multi-institutional study, it lacks of consistency 
with respect to surgical technique in TURBTs and RC, and histopathological reporting since 
there was no central pathology review. Essentially all patients in this study underwent white 
light cystoscopy, although this was not captured explicitly. The rate of CIS detection would likely 
be higher if patients had been evaluated with blue light cystoscopy CIS [15,16], and the latter 
would allow for a more complete analysis of the impact of CIS in the context of NAC.  
 
In conclusion, our multicenter retrospective data did not indicate worse outcome after 
neoadjuvant or induction chemotherapy and RC in patients with concomitant CIS of the bladder 
at TURBT. This study  suggests that these patients may not be treated  differently than patients 
without CIS at TURBT.  
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